Advertorial

Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development

Posted: 12 December 2019 | | No comments yet

Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.

A recent market survey targeting antibody therapeutics professionals in pharma, biotech, academia, CDMOs and CROs found that 81 percent of respondents were involved in mAb development, with the main development challenges encountered at the discovery and target identification stage. Most respondents to the survey indicated that the industry needs technologies that can more accurately identify lead molecules.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: ForteBio

Related organisations

Send this to a friend